Squarepoint’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $72.5M | Sell |
1,154,441
-1,373,007
| -54% | -$95.6M | 0.09% | 228 |
|
|
2025
Q4 | $168M | Buy |
2,527,448
+1,441,354
| +133% | +$93.2M | 0.18% | 104 |
|
|
2025
Q3 | $73.1M | Buy |
1,086,094
+1,053,912
| +3,275% | +$83.4M | 0.07% | 297 |
|
|
2025
Q2 | $2.81M | Sell |
32,182
-111,336
| -78% | -$8.73M | ﹤0.01% | 1852 |
|
|
2025
Q1 | $9.8M | Buy |
143,518
+65,513
| +84% | +$5.35M | 0.01% | 1037 |
|
|
2024
Q4 | $6.07M | Sell |
78,005
-661,966
| -89% | -$49M | 0.01% | 1489 |
|
|
2024
Q3 | $49.6M | Buy |
739,971
+398,020
| +116% | +$32.7M | 0.08% | 244 |
|
|
2024
Q2 | $38.8M | Buy |
341,951
+216,282
| +172% | +$27.3M | 0.06% | 324 |
|
|
2024
Q1 | $17.4M | Buy |
125,669
+22,218
| +21% | +$2.79M | 0.03% | 681 |
|
|
2023
Q4 | $12.8M | Sell |
103,451
-241,043
| -70% | -$24.6M | 0.02% | 797 |
|
|
2023
Q3 | $32.1M | Sell |
344,494
-200,118
| -37% | -$22.6M | 0.08% | 283 |
|
|
2023
Q2 | $70M | Buy |
544,612
+260,196
| +91% | +$31.5M | 0.21% | 82 |
|
|
2023
Q1 | $33M | Buy |
284,416
+233,622
| +460% | +$26.2M | 0.13% | 150 |
|
|
2022
Q4 | $5.75M | Sell |
50,794
-398,291
| -89% | -$43.7M | 0.02% | 771 |
|
|
2022
Q3 | $36.2M | Buy |
449,085
+109,236
| +32% | +$9.25M | 0.18% | 102 |
|
|
2022
Q2 | $25.3M | Buy |
339,849
+276,941
| +440% | +$25.3M | 0.14% | 157 |
|
|
2022
Q1 | $8.05M | Sell |
62,908
-227,908
| -78% | -$24.9M | 0.03% | 520 |
|
|
2021
Q4 | $39M | Buy |
290,816
+283,268
| +3,753% | +$40.7M | 0.1% | 165 |
|
|
2021
Q3 | $1.03M | Sell |
7,548
-9,572
| -56% | -$1.21M | ﹤0.01% | 1549 |
|
|
2021
Q2 | $1.83M | Sell |
17,120
-134,688
| -89% | -$12.9M | 0.01% | 1238 |
|
|
2021
Q1 | $13.6M | Buy |
151,808
+141,768
| +1,412% | +$13.3M | 0.08% | 280 |
|
|
2020
Q4 | $928K | Sell |
10,040
-1,960
| -16% | -$175K | 0.01% | 1388 |
|
|
2020
Q3 | $1.24M | Sell |
12,000
-25,252
| -68% | -$2.64M | 0.02% | 879 |
|
|
2020
Q2 | $3.77M | Sell |
37,252
-46,844
| -56% | -$4.19M | 0.06% | 420 |
|
|
2020
Q1 | $5.66M | Sell |
84,096
-63,904
| -43% | -$3.98M | 0.14% | 167 |
|
|
2019
Q4 | $8.09M | Buy |
+148,000
| New | +$7.02M | 0.05% | 362 |
|
|
2019
Q3 | – | Sell |
-276,056
| Closed | -$10.3M | – | 2408 |
|
|
2019
Q2 | $10.3M | Buy |
+276,056
| New | +$8.68M | 0.1% | 247 |
|
|
2019
Q1 | – | Sell |
-526,360
| Closed | -$15.8M | – | 2209 |
|
|
2018
Q4 | $15.8M | Buy |
526,360
+246,332
| +88% | +$7.81M | 0.18% | 125 |
|
|
2018
Q3 | $10M | Sell |
280,028
-496,228
| -64% | -$15.4M | 0.12% | 226 |
|
|
2018
Q2 | $18.4M | Buy |
+776,256
| New | +$16.5M | 0.24% | 90 |
|
|
2018
Q1 | – | Sell |
-488,348
| Closed | -$7.01M | – | 1788 |
|
|
2017
Q4 | $7.01M | Buy |
488,348
+458,896
| +1,558% | +$5.96M | 0.12% | 189 |
|
|
2017
Q3 | $360K | Buy |
+29,452
| New | +$521K | 0.01% | 1097 |
|
|
2016
Q3 | – | Sell |
-12,800
| Closed | -$254K | – | 1069 |
|
|
2016
Q2 | $254K | Buy |
+12,800
| New | +$218K | 0.02% | 801 |
|
|
2016
Q1 | – | Sell |
-10,800
| Closed | -$221K | – | 1224 |
|
|
2015
Q4 | $221K | Buy |
+10,800
| New | +$225K | 0.02% | 944 |
|
|
2015
Q3 | – | Sell |
-12,000
| Closed | -$240K | – | 456 |
|
|
2015
Q2 | $240K | Buy |
+12,000
| New | +$211K | 0.08% | 335 |
|
Other funds holding DXCM
VCM
VPM
Squarepoint's DXCM Position: Q1 2026 in Review
Squarepoint reduced its DexCom (DXCM) stake by 54% in Q1 2026, selling an estimated $95.6M and leaving 1,154,441 shares worth $72.5M. The position accounts for 0.09% of the portfolio, ranked #228.
Squarepoint first reported a position in DXCM in Q2 2015 and has held it in 35 quarters since. The position peaked at $168M in Q4 2025. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Squarepoint held 1,154,441 shares of DexCom worth $72.5M as of Q1 2026.
- Squarepoint sold 1,373,007 DexCom shares in Q1 2026, an estimated $95.6M.
- DexCom made up 0.09% of Squarepoint's portfolio in Q1 2026, its #228 holding.
- Squarepoint first reported a position in DexCom in Q2 2015 and has held it in 35 quarters since.
- Squarepoint's DexCom position peaked at $168M in Q4 2025.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.